histamine has been researched along with Pyrexia in 39 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current study evaluated the pharmacological activity of gabapentin (GBP) and its salicylaldehyde derivative (gabapentsal; [2-(1-(((2-hydroxybenzylidene) amino) methyl) cyclohexyl) acetic acid]; GPS) in well-established mouse models of nociceptive pain, inflammatory edema, and pyrexia at doses of 25-100 mg/kg." | 8.02 | Pharmacological evaluation of the gabapentin salicylaldehyde derivative, gabapentsal, against tonic and phasic pain models, inflammation, and pyrexia. ( Ahmad, N; Akbar, S; Amin, MU; Islam, NU; Khurram, M; Sewell, RDE; Shahid, M; Subhan, F; Ullah, I; Ullah, N; Ullah, R, 2021) |
| "0 mg ovalbumin (OVA) by gavage every day for 9 weeks, and active systemic anaphylaxis (ASA) was induced by intraperitoneal injection of OVA." | 7.70 | Induction of active systemic anaphylaxis by oral sensitization with ovalbumin in mast-cell-deficient mice. ( Akiyama, H; Goda, Y; Okunuki, H; Sakushima, J; Sawada, JI; Teshima, R; Toyoda, M, 2000) |
| " All reported adverse events were included in the analysis." | 6.71 | Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. ( Agarwala, SS; Gehlsen, KR; Glaspy, J; Kass, CL; Naredi, P; O'Day, SJ, 2003) |
| " The mean duration of fever in the Ergoferon and oseltamivir groups was 2." | 5.22 | Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. ( Andrianova, E; Averyanov, A; Bart, B; Epstein, O; Minina, E; Putilovskiy, M; Rafalsky, V, 2016) |
| " The current study evaluated the pharmacological activity of gabapentin (GBP) and its salicylaldehyde derivative (gabapentsal; [2-(1-(((2-hydroxybenzylidene) amino) methyl) cyclohexyl) acetic acid]; GPS) in well-established mouse models of nociceptive pain, inflammatory edema, and pyrexia at doses of 25-100 mg/kg." | 4.02 | Pharmacological evaluation of the gabapentin salicylaldehyde derivative, gabapentsal, against tonic and phasic pain models, inflammation, and pyrexia. ( Ahmad, N; Akbar, S; Amin, MU; Islam, NU; Khurram, M; Sewell, RDE; Shahid, M; Subhan, F; Ullah, I; Ullah, N; Ullah, R, 2021) |
| " Nevertheless, the anti-inflammatory activity was tested in carrageenan induced paw edema and histamine induced inflammatory tests." | 3.78 | Antipyretic, analgesic and anti-inflammatory activity of Viola betonicifolia whole plant. ( Khan, H; Muhammad, N; Saeed, M, 2012) |
| "Blood histamine levels were investigated by a fluorometric method in infants and children admitted to hospital with bronchiolitis, non-wheezing bronchitis, acute infections of the urinary tract, skin and ear-nose-throat, gastroenteritis, or hyperthermia of unknown aetiology." | 3.71 | Blood histamine levels (BHL) in infants and children with respiratory and non-respiratory diseases. ( de Blic, J; Galoppin, L; Le Bourgeois, M; Paupe, J; Ponvert, C; Scheinmann, P, 2001) |
| "0 mg ovalbumin (OVA) by gavage every day for 9 weeks, and active systemic anaphylaxis (ASA) was induced by intraperitoneal injection of OVA." | 3.70 | Induction of active systemic anaphylaxis by oral sensitization with ovalbumin in mast-cell-deficient mice. ( Akiyama, H; Goda, Y; Okunuki, H; Sakushima, J; Sawada, JI; Teshima, R; Toyoda, M, 2000) |
| "Influenza was confirmed in 52 patients by QuickVue rapid diagnosis." | 2.77 | [Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial]. ( Andrianova, EN; Aver'ianov, AV; Babkin, AP; Bart, BIa; Epshteĭn, OI; Kostinov, MP; Kozyrev, OA; Minina, ES; Nechaev, VB; Petrov, DV; Putilovskiĭ, MA; Sel'kova, EP; Volchetskiĭ, AL, 2012) |
| " All reported adverse events were included in the analysis." | 2.71 | Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. ( Agarwala, SS; Gehlsen, KR; Glaspy, J; Kass, CL; Naredi, P; O'Day, SJ, 2003) |
| " Dose-response curves for agonists and the effects of antagonists are often undetermined." | 2.37 | The pharmacology of fever. ( Dascombe, MJ, 1985) |
| "Histamine has been suggested to participate in seizure control." | 1.39 | Effect of hyperthermia on histamine blood level and convulsive behavior in infant rats. ( Fereidoni, J; Gholipoor, P; Roshan-Milani, S; Saboory, E, 2013) |
| "Pargyline was without effect." | 1.25 | Hypothermia produced in mice by histamine acting on the central nervous system. ( Shaw, GG, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (53.85) | 18.7374 |
| 1990's | 4 (10.26) | 18.2507 |
| 2000's | 6 (15.38) | 29.6817 |
| 2010's | 6 (15.38) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Mohseni, M | 1 |
| Raissi, V | 1 |
| Sharifan, Y | 1 |
| Barikro, K | 1 |
| Amiri, S | 1 |
| Mohseni, MS | 1 |
| Raeisi, F | 1 |
| Masoumi, K | 1 |
| Khodakarami, S | 1 |
| Raiesi, O | 1 |
| Ahmad, N | 1 |
| Subhan, F | 1 |
| Islam, NU | 1 |
| Shahid, M | 1 |
| Ullah, N | 1 |
| Ullah, R | 1 |
| Khurram, M | 1 |
| Amin, MU | 1 |
| Akbar, S | 1 |
| Ullah, I | 1 |
| Sewell, RDE | 1 |
| Lkhagvasuren, B | 1 |
| Oka, T | 1 |
| Gholipoor, P | 1 |
| Saboory, E | 1 |
| Roshan-Milani, S | 1 |
| Fereidoni, J | 1 |
| Rafalsky, V | 1 |
| Averyanov, A | 1 |
| Bart, B | 1 |
| Minina, E | 1 |
| Putilovskiy, M | 1 |
| Andrianova, E | 1 |
| Epstein, O | 1 |
| Carlin, JL | 1 |
| Jain, S | 1 |
| Gizewski, E | 1 |
| Wan, TC | 1 |
| Tosh, DK | 1 |
| Xiao, C | 1 |
| Auchampach, JA | 1 |
| Jacobson, KA | 1 |
| Gavrilova, O | 1 |
| Reitman, ML | 1 |
| FANBURG, SJ | 1 |
| FROMMEL, E | 2 |
| BECK, IT | 1 |
| WENT, F | 1 |
| Muhammad, N | 1 |
| Saeed, M | 1 |
| Khan, H | 1 |
| Aver'ianov, AV | 1 |
| Babkin, AP | 1 |
| Bart, BIa | 1 |
| Volchetskiĭ, AL | 1 |
| Minina, ES | 1 |
| Kozyrev, OA | 1 |
| Kostinov, MP | 1 |
| Petrov, DV | 1 |
| Sel'kova, EP | 1 |
| Putilovskiĭ, MA | 1 |
| Nechaev, VB | 1 |
| Epshteĭn, OI | 1 |
| Andrianova, EN | 1 |
| O'Day, SJ | 1 |
| Agarwala, SS | 1 |
| Naredi, P | 1 |
| Kass, CL | 1 |
| Gehlsen, KR | 1 |
| Glaspy, J | 1 |
| BLISS, EL | 1 |
| MIGEON, CJ | 1 |
| EIK-NES, K | 1 |
| SANDBERG, AA | 1 |
| SAMUELS, LT | 1 |
| FLEURY, C | 1 |
| VON LEDEBUR, I | 1 |
| BEGUIN, M | 1 |
| CZARNECKI, E | 1 |
| KIERSZ, J | 1 |
| KRAWCZAK, J | 1 |
| STRABURZYNSKI, G | 1 |
| RASKOVA, H | 1 |
| VANECEK, J | 1 |
| SYMBAS, PN | 1 |
| JELLINEK, M | 1 |
| COOPER, T | 1 |
| HANLON, C | 1 |
| RUBIN, B | 1 |
| PIALA, JJ | 1 |
| BURKE, JC | 1 |
| CRAVER, BN | 1 |
| SANTESSON, G | 1 |
| TOMENIUS, J | 1 |
| Chiba, S | 1 |
| Itateyama, E | 1 |
| Oka, K | 1 |
| Masaki, T | 1 |
| Sakata, T | 1 |
| Yoshimatsu, H | 1 |
| Kaplan, HR | 1 |
| Wolke, RE | 1 |
| Malone, MH | 1 |
| Deev, LI | 1 |
| Goncharenko, EN | 1 |
| Baĭzhumanov, AA | 1 |
| Akhalaia, MIa | 1 |
| Antonova, SV | 1 |
| Shestakova, SV | 1 |
| Okunuki, H | 1 |
| Teshima, R | 1 |
| Sakushima, J | 1 |
| Akiyama, H | 1 |
| Goda, Y | 1 |
| Toyoda, M | 1 |
| Sawada, JI | 1 |
| Iwase, M | 2 |
| Izumizaki, M | 1 |
| Kanamaru, M | 2 |
| Homma, I | 2 |
| Ponvert, C | 1 |
| Galoppin, L | 1 |
| Paupe, J | 1 |
| de Blic, J | 1 |
| Le Bourgeois, M | 1 |
| Scheinmann, P | 1 |
| van der Zwan, JC | 1 |
| Orie, NG | 1 |
| de Vries, K | 1 |
| Winning, AJ | 1 |
| Widdicombe, JG | 1 |
| Pereverzev, VA | 1 |
| Kubarko, AI | 1 |
| Balakleevskiĭ, AI | 1 |
| Gubkina, NI | 1 |
| Kul'baev, IS | 1 |
| Kostiushina, NV | 1 |
| Timoshin, SS | 1 |
| Shvets, SI | 1 |
| Radivoz, MI | 1 |
| Aleksandrovich, AG | 1 |
| Mel'nik, EI | 1 |
| Loveday, C | 1 |
| Bingham, JS | 1 |
| Dascombe, MJ | 1 |
| Schrádi, A | 1 |
| Bene, J | 1 |
| Tokumaru, T | 1 |
| Pekarskiĭ, DE | 1 |
| Merkal, RS | 1 |
| Kopecky, KE | 1 |
| Larsen, AB | 1 |
| Shaw, GG | 1 |
| Glenn, EM | 1 |
| Rohloff, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza[NCT01804946] | Phase 4 | 161 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pneumonia, sinusitis, otitis media are examples of the influenza complications (NCT01804946)
Timeframe: Day 1 to Day 7
| Intervention | Percentage of participants (Number) |
|---|---|
| Ergoferon Group | 0 |
| Oseltamivir Group | 2 |
The quality of life was assessed in influenza patients at baseline and at the end of the treatment period using the European Quality of Life Questionnaire (EQ5D) measuring the health status by five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression (each dimension is assessed by 1 to 3 point scale; the minimum score 5 points refers to the best status, 15 points refers to the worst status). (NCT01804946)
Timeframe: Day 7 vs. Day 1
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Day 1 | Day 7 | |
| Ergoferon Group | 9.5 | 5.4 |
| Oseltamivir Group | 9.4 | 5.4 |
The patient subjective health status assessment was based on Visual Analogue Scale - VAS). VAS includes a rating of current health status from 0 (worst) to 100 (best). (NCT01804946)
Timeframe: Day 7 vs. Day 1
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Day 1 | Day 7 | |
| Ergoferon Group | 41.6 | 87.7 |
| Oseltamivir Group | 46.2 | 88.0 |
The axillary temperature was assessed during a physical examination at Day 1, 3 and 7; axillary temperature was assessed in degrees (Celsius, °С) (NCT01804946)
Timeframe: on days 1, 3 and 7 of the observation
| Intervention | °C (Mean) | ||
|---|---|---|---|
| Axillary temperature, Day 1 | Axillary temperature, Day 3 | Axillary temperature, Day 7 | |
| Ergoferon Group | 38.3 | 37.0 | 36.5 |
| Oseltamivir Group | 38.3 | 37.0 | 36.6 |
Axillary temperature (morning and evening) decline to or below 37.0 ºС (without subsequent increase during ≥24 h) (NCT01804946)
Timeframe: Day 1 to Day 5
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Evening, Day 1 | Evening, Day 2 | Evening, Day 3 | Evening, Day 4 | Evening, Day 5 | |
| Ergoferon Group (EG) | 4 | 15 | 41 | 68 | 84 |
| Oseltamivir Goup (OG) | 1 | 15 | 43 | 72 | 88 |
Assessment of the proportion of subjects with no clinical symptoms of the disease (fever, common and respiratory symptoms) at Study Day 7 (Visit 3). The severity of influenza symptoms was assessed by a physician with 0 to 3 point scale, where 0 means no symptom, 1=mild symptom, 2=moderate symptom, and 3=severe symptom (NCT01804946)
Timeframe: on the day 7 of the observation
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Fever | Common symptoms | Respiratory symptoms | All symptoms | |
| Ergoferon Group | 100 | 61 | 83 | 47 |
| Oseltamivir Group | 100 | 64 | 76 | 49 |
The severity of influenza symptoms was assessed during a physical examination at Day 1, 3 and 7; common (10 symptoms) and respiratory (5 symptoms) symptom's total score was assessed with using the point scale: 0=No symptom; 1=Mild symptom; 2=Moderate symptom ; 3=Severe symptom. The Common Symptoms total score ranged from 0 (no symptoms) to 30 (severe symptoms). The Respiration Symptoms total score ranged from 0 (no symptoms) to 15 (severe symptoms) (NCT01804946)
Timeframe: on days 1, 3 and 7 of the observation
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Common symptoms, Day 1 | Common symptoms, Day 3 | Common symptoms, Day 7 | Respiratory symptoms, Day 1 | Respiratory symptoms, Day 3 | Respiratory symptoms, Day 7 | |
| Ergoferon Group | 19.0 | 9.2 | 2.3 | 6.1 | 4.3 | 1.3 |
| Oseltamivir Group | 18.6 | 7.8 | 1.9 | 5.9 | 4.0 | 1.4 |
A subject recorded the number of antipyretic intake in patient diary. (NCT01804946)
Timeframe: Day 1 to Day 5
| Intervention | Number of Doses (Mean) | ||||
|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | |
| Ergoferon Group | 0.65 | 0.40 | 0.19 | 0.01 | 0.00 |
| Oseltamivir Group | 0.72 | 0.49 | 0.15 | 0.03 | 0.01 |
"Time to resolution was considered as time to the absence of any flu symptom. Absence of symptoms was considered as axillary temperature decline to or below 37.0 ºС without subsequent rise, resolution of the common and respiratory symptoms.~The duration of a symptom was defined by physician recorded presence/absence of the symptoms during a physical examination at Day 1 to Day 7." (NCT01804946)
Timeframe: Day 1 to Day 7
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Fever | Common symptoms | Respiratory symptoms | All influenza symptoms | |
| Ergoferon Group | 2.1 | 2.6 | 2.7 | 2.6 |
| Oseltamivir Group | 2.3 | 2.4 | 2.6 | 2.5 |
3 reviews available for histamine and Pyrexia
| Article | Year |
|---|---|
Therapeutic Status of Famotidine in COVID-19 Patients: A Review.
Topics: COVID-19 Drug Treatment; Famotidine; Fever; Histamine; Humans; SARS-CoV-2 | 2022 |
PHARMACOLOGY OF BACTERIAL TOXINS.
Topics: Abortion, Induced; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Antitoxins | 1964 |
The pharmacology of fever.
Topics: Acetylcholine; Amino Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biogenic Amines; Body | 1985 |
5 trials available for histamine and Pyrexia
| Article | Year |
|---|---|
Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial.
Topics: Adolescent; Adult; Aged; Antibodies; Antiviral Agents; CD4 Antigens; Female; Fever; Histamine; Human | 2016 |
[Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial].
Topics: Adolescent; Adult; Antipyretics; Antiviral Agents; Body Temperature; CD4 Antigens; Female; Fever; Hi | 2012 |
Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chills; Female; F | 2003 |
Biphasic reaction after inhalation of Haemophilus influenzae in patients with chronic nonspecific lung disease.
Topics: Adult; Antibodies, Bacterial; Asthma; Clinical Trials as Topic; Complement C3; Complement C4; Cromol | 1975 |
[Results in the therapy of bronchial asthma using histaglobine].
Topics: Adolescent; Adult; Asthma; Child; Clinical Trials as Topic; Drug Combinations; Female; Fever; gamma- | 1972 |
31 other studies available for histamine and Pyrexia
| Article | Year |
|---|---|
Pharmacological evaluation of the gabapentin salicylaldehyde derivative, gabapentsal, against tonic and phasic pain models, inflammation, and pyrexia.
Topics: Aldehydes; Analgesics; Animals; Anti-Inflammatory Agents; Antipyretics; Carrageenan; Disease Models, | 2021 |
The histaminergic system is involved in psychological stress-induced hyperthermia in rats.
Topics: Animals; Body Temperature Regulation; Cimetidine; Fever; Histamine; Histamine Agonists; Imidazoles; | 2017 |
Effect of hyperthermia on histamine blood level and convulsive behavior in infant rats.
Topics: Animals; Animals, Newborn; Anti-Asthmatic Agents; Body Temperature; Cromolyn Sodium; Disease Models, | 2013 |
Hypothermia in mouse is caused by adenosine A
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A3 Receptor Agonists; Adenosine Monophosphate; | 2017 |
Pyribenzamine fever; report of a case.
Topics: Anti-Allergic Agents; Fever; Histamine; Histamine Antagonists; Histamine H1 Antagonists; Tripelennam | 1948 |
Studies in the field of fever; histamine and dinitrogen fever.
Topics: Fever; Histamine; Histamine Agents; Nitro Compounds | 1947 |
Blutcholin, acetylcholine and histamine for fever treatment and malaria attack.
Topics: Acetylcholine; Blood; Choline; Fever; Histamine; Humans; Malaria | 1946 |
Antipyretic, analgesic and anti-inflammatory activity of Viola betonicifolia whole plant.
Topics: Acetaminophen; Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Antipyretics; Behavior, A | 2012 |
The effects of insulin, histamine, bacterial pyrogen, and the antabuse-alcohol reaction upon the levels of 17-hydroxycorticosteroids in the peripheral blood of man.
Topics: 17-Hydroxycorticosteroids; Adrenal Cortex; Adrenal Cortex Hormones; Blood; Disulfiram; Endotoxins; E | 1954 |
[Deviations in the pharmacodynamic action of various drugs by hypo- and hyperthermia. 2].
Topics: Acetylcholine; Aminobutyrates; Amphetamine; Amphetamines; Atropine; Chlordiazepoxide; Chlorpromazine | 1962 |
[ON THE INFLUENCE OF HYPERTHERMIA ON THE COURSE OF EXPERIMENTAL SHOCK].
Topics: Anaphylaxis; Dinitrophenols; Dogs; Fever; Histamine; Kymography; Peptones; Pharmacology; Research; S | 1963 |
EFFECT OF HYPERTHERMIA ON PLASMA CATECHOLAMINES AND HISTAMINE.
Topics: Blood Chemical Analysis; Catecholamines; Dogs; Fever; Histamine; Histamine Release; Plasma; Research | 1964 |
A NEW, POTENT AND SPECIFIC SEROTONIN INHIBITOR, (SQ 10,643) 2'-(3-DIMETHYLAMINOPROPYLTHIO) CINNAMANILIDE HYDROCHLORIDE: ANTISEROTONIN ACTIVITY ON UTERUS AND ON GASTROINTESTINAL, VASCULAR, AND RESPIRATORY SYSTEMS OF ANIMALS.
Topics: 5-Hydroxytryptophan; Acetylcholine; Blood Pressure; Bronchi; Cinanserin; Dextrans; Edema; Female; Fe | 1964 |
A study of histamine-induced gastric secretion during artificial fever.
Topics: Body Temperature; Fever; Gastric Juice; Histamine; Stomach; Temperature | 1950 |
Hypothalamic neuronal histamine modulates febrile response but not anorexia induced by lipopolysaccharide.
Topics: Animals; Anorexia; Fever; Histamine; Hypothalamus; Lipopolysaccharides; Male; Neurons; Rats; Rats, W | 2005 |
Anti-inflammatory evaluation of cryogenine.
Topics: Analgesics; Animals; Bradykinin; Carrageenan; Drinking; Drug Antagonism; Edema; Female; Fever; Guine | 1967 |
[Protective effect of carnosine in hyperthermia].
Topics: Amine Oxidase (Copper-Containing); Animals; Carnosine; Cytochrome P-450 Enzyme System; Fever; Histam | 1997 |
Induction of active systemic anaphylaxis by oral sensitization with ovalbumin in mast-cell-deficient mice.
Topics: Administration, Oral; Anaphylaxis; Animals; Body Weight; Disease Models, Animal; Female; Fever; Food | 2000 |
Involvement of central histaminergic neurons in polypnea induced by hyperthermia in rabbits.
Topics: Animals; Enzyme Inhibitors; Fever; Histamine; Histamine H1 Antagonists; Male; Methylhistidines; Neur | 2001 |
Blood histamine levels (BHL) in infants and children with respiratory and non-respiratory diseases.
Topics: Child, Preschool; Communicable Diseases; Female; Fever; Gastroenteritis; Histamine; Humans; Infant; | 2001 |
Neuronal histamine release elicited by hyperthermia mediates tracheal dilation and pressor response.
Topics: Animals; Blood Pressure; Body Temperature; Chlorpheniramine; Fever; Histamine; Histamine Antagonists | 2001 |
The effect of lung reflexes on the pattern of breathing in cats.
Topics: Animals; Biguanides; Cats; Female; Fever; Histamine; Lung; Male; Oxygen; Phrenic Nerve; Reflex; Resp | 1976 |
[The role of serotonin and histamine in enhancing body resistance to extreme exposures].
Topics: Acute Disease; Animals; Dose-Response Relationship, Drug; Female; Fever; Histamine; Hypercapnia; Hyp | 1992 |
[The microhemodynamics and lymph flow in the small intestine under the action of histamine against a background of water loading and hyperthermia in dogs].
Topics: Animals; Capillary Permeability; Dogs; Fever; Hemodynamics; Histamine; Hydrostatic Pressure; Intesti | 1992 |
[Effects of dalargin on the proliferative processes of the gastric epithelium under repeated action of different stressors].
Topics: Animals; Cell Division; DNA; Enkephalin, Leucine-2-Alanine; Epithelial Cells; Epithelium; Fever; His | 1991 |
Changes in intravascular complement, kininogen, and histamine during Jarisch-Herxheimer reaction in secondary syphilis.
Topics: Adult; Blood Pressure; Complement Activation; Complement C3; Complement C4; Complement Inactivator P | 1985 |
Nature of febrile response to intravenous injection of large amounts of herpes simplex virus in guinea pigs.
Topics: Animals; Epinephrine; Fever; Guinea Pigs; Herpes Simplex; Histamine; Hot Temperature; Hydrocortisone | 1968 |
[On the pathophysiology and therapy of postoperative hyperthermic syndrome in children].
Topics: Adrenal Cortex Hormones; Adrenal Glands; Female; Fever; Histamine; Histamine H1 Antagonists; Humans; | 1967 |
Immunologic mechanisms in bovine paratuberculosis.
Topics: Animals; Cattle; Cattle Diseases; Desensitization, Immunologic; Diarrhea; Ergolines; Fever; Histamin | 1970 |
Hypothermia produced in mice by histamine acting on the central nervous system.
Topics: Amphetamine; Animals; Atropine; Body Temperature; Body Temperature Regulation; Central Nervous Syste | 1971 |
Antiarthritic and antiinflammatory effects of certain prostaglandins.
Topics: Adrenal Glands; Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Blood Sedimentation; Body Wei | 1972 |